Delay = Buy Opportunity, page-2

First 2 Last

Share
Profile

Follow
Mozzarc

4,436 Posts.

7008

26/04/21

10:06

Post #: 52716056
Share

Originally posted by Senpras89: ↑

Hello Everyone,

I just thought I would provide my two cents regarding the news release from Paradigm and the FDA.
I thought the update was 90% positive and 10% negative.

The FDA typically want to be thorough for this process. I believe that since Friday 26th March, Paradigm have sufficiently and adequately answered the "few" questions provided by the FDA. The bulk of questions have probably already been answered regarding the actual clinical data.

Due to the massive submission of a 30,000 page application, it is common that the FDA would still have some pending questions. I think it is very positive that most of the questions from their brief discussion with the FDA will be about the submission of non-clinical data, rather than actual clinical / scientific data. I believe this application process will ultimately be completed soon. The FDA can be rigid with their guidelines, but in my experience, this is typical, but definitely should not be interpreted as a huge negative.

My 10% negativity in the announcement is more due to the time delay, but I would always be looking to top up a position in times where the market becomes impatient. Nothing material has impacted the long-term story of the company. The times where I would be looking to top up are when there is a bad earnings release, a regulatory issue or simply just market neglect.

This inefficiency could last for a day, or a week, or occasionally longer, but will be short-lived once Paradigm easily answer pending questions. Your job as an investor is to take advantage when these dislocations occur.

Stay safe everyone, I am confident that we will be opening the indication soon.

Expand

Well written, I agree.

PAR Price at posting: $2.55 Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban

PNN

Power gets set for 1000-metre maiden drilling program in Brazil

US election outcomes: Key economic and market takeaways

First 2 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 23.0¢		Change -0.010(4.17%)		Mkt cap ! $80.48M

Open	High	Low	Value	Volume
25.0¢	25.0¢	22.5¢	$167.1K	714.6K

Buyers (Bids)

No.	Vol.	Price($)
8	120730	22.0¢

Sellers (Offers)

Price($)	Vol.	No.
23.0¢	49999	1

View Market Depth

No.	Vol.	Price($)
8	120730	0.220
7	128954	0.215
12	201568	0.210
8	108042	0.205
30	839672	0.200

Price($)	Vol.	No.
0.230	49999	1
0.235	2500	1
0.240	44600	1
0.245	145349	4
0.250	151040	6

Last trade - 16.10pm 18/11/2024 (20 minute delay)

PAR (ASX) Chart

Delay = Buy Opportunity, page-2

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban

Power gets set for 1000-metre maiden drilling program in Brazil

US election outcomes: Key economic and market takeaways

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Delay = Buy Opportunity, page-2

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Quit before you're fired: Russia bans uranium exports to USA, duplicating extant US ban

Power gets set for 1000-metre maiden drilling program in Brazil

US election outcomes: Key economic and market takeaways

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News